(Q45162015)

10 December 2017

title

Protective effect of montelukast on lower and upper respiratory tract responses to short-term cat allergen exposure (English)

1 reference

10 December 2017

2

Jonathan Corren

1 reference

10 December 2017

Tamara T Perry

1

1 reference

10 December 2017

George Philip

3

1 reference

10 December 2017

Eric H Kim

4

1 reference

10 December 2017

Mary Kay Conover-Walker

5

1 reference

10 December 2017

Marie-Pierre Malice

6

1 reference

10 December 2017

Rachid Massaad

7

1 reference

10 December 2017

S Balachandra Dass

8

1 reference

10 December 2017

Theodore F Reiss

9

1 reference

10 December 2017

Robert A Wood

10

1 reference

10 December 2017

language of work or name

1 reference

1 November 2004

1 reference

Annals of Allergy, Asthma & Immunology

10 December 2017

published in

1 reference

10 December 2017

volume

93

1 reference

10 December 2017

issue

5

1 reference

10 December 2017

page(s)

431-438

1 reference

The rising trends in asthma and allergic disease

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Quality of life in allergic rhinitis and asthma. A population-based study of young adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Allergic rhinobronchitis: the asthma-allergic rhinitis link

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Epidemiologic evidence for asthma and rhinitis comorbidity.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

1 reference

7 January 2021

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Release of leukotrienes in patients with bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Leukotriene C4 release in upper respiratory mucosa during natural exposure to ragweed in ragweed-sensitive children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Immediate and late inflammatory responses to ragweed antigen challenge of the peripheral airways in allergic asthmatics. Cellular, mediator, and permeability changes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Peptide Leukotriene Release after Antigen Challenge in Patients Sensitive to Ragweed

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

A randomized controlled trial of intravenous montelukast in acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Montelukast improves symptoms of seasonal allergic rhinitis over a 4‐week treatment period

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

The role and remediation of animal allergens in allergic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

The effects of intranasal steroids on nasal and pulmonary responses to cat exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Effects of zafirlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

A randomized, double-blind, placebo-controlled trial of the effect of zafirlukast on upper and lower respiratory responses to cat challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

The efficacy of montelukast in the treatment of cat allergen-induced asthma in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

The aerodynamic characteristics of cat allergen

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Rhinitis and asthma: evidence for respiratory system integration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Relationship of daytime asthma symptom frequency to morning peak expiratory flow.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Correlation of airway obstruction and patient-reported endpoints in clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Variability and lack of predictive ability of asthma end-points in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

Cat antigen in homes with and without cats may induce allergic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961409-3

7 January 2021

10.1016/S1081-1206(10)61409-3

Identifiers

DOI

1 reference

10 December 2017

1 reference